文献速递冠心病高血压

AβYSS试验:心梗后中断β受体阻滞剂对血压和心率的影响

Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial.
PubMed 文献 · Eur Heart J · 2025-01-01

AβYSS试验纳入3698例心梗后患者,随机分为中断或继续β受体阻滞剂治疗,中位随访3.0年。中断组6个月时收缩压升高3.7 mmHg、舒张压升高3.3 mmHg、静息心率增加10 b.p.m.,且持续整个随访期。有高血压史患者中断β受体阻滞剂后主要终点事件风险增加更明显。

要点

  • 心梗后中断β受体阻滞剂可致收缩压升高3.7 mmHg、舒张压升高3.3 mmHg、心率增加10 b.p.m.,持续存在。
  • 高血压患者中断β受体阻滞剂后主要终点事件风险差为5.02%,需谨慎。
  • 即使增加降压药物,中断组血压和心率升高仍持续。

核心结论

  • 无并发症心梗后中断β受体阻滞剂治疗导致血压和心率持续升高,可能对结局产生不良影响,尤其在有高血压史的患者中。

研究设计与样本

  • AβYSS试验的事后分析,纳入3698例心梗后随机中断或继续β受体阻滞剂的患者,中位随访3.0年。

临床怎么用

  • 心梗后无并发症患者中断β受体阻滞剂可能导致血压和心率持续升高,应密切监测。
  • 有高血压史的心梗患者中断β受体阻滞剂可能增加不良事件风险,需谨慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This study aims to report the effects of β-blocker interruption on blood pressure (BP) and heart rate (HR) in the AβYSS trial where patients were randomized to interruption or continuation of β-blocker treatment after a myocardial infarction (MI). METHODS: Changes in HR and BP from baseline to post-randomization are reported using linear mixed repeated model, in the 3698 patients of the AβYSS trial with a median follow-up of 3.0 years. Additionally, changes in HR and BP and the impact on the primary endpoint (death, MI, stroke, hospitalization for cardiovascular reason) in the pre-specified subgroups of patients with or without history of hypertension were assessed using linear mixed repeated and adjusted Cox proportional hazards model, respectively. RESULTS: β-blocker interruption was associated with significant increase {least square mean difference [95% confidence interval (CI)]} in systolic BP [+3.7 (2.6, 4.8) mmHg, P < .001], diastolic BP [+3.3 (2.6, 4.0) mmHg, P < .001], and resting HR [+10 [9, 11) b.p.m., P < .001] at 6 months that persisted over the duration of follow-up despite an increase in antihypertensive drugs in the β-blocker interruption group. The effects were observed in both hypertensive (43% of the population) and non-hypertensive patients. Hypertensive patients were at higher risk of events (25.8% vs. 19.2%) as compared with patients without hypertension (adjusted hazard ratio 1.18, 95% CI 1.01-1.36, P = .03). Patients with hypertension had a particularly marked increase in the primary endpoint (risk difference 5.02%, 0.72%-9.32%, P = .014) when randomized to β-blocker interruption. CONCLUSIONS: Interruption of β-blocker treatment after an uncomplicated MI led to a sustained increase in BP and HR, with potentially deleterious effects on outcomes, especially in patients with history of hypertension.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Procopi, Zeitouni, Kerneis, et al. Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial. Eur Heart J. 2025. PMID: 40401436. doi:10.1093/eurheartj/ehaf170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。